Oxytetracycline-induced thrombocytopenic purpura
نویسندگان
چکیده
منابع مشابه
Rosuvastatin-Induced Thrombocytopenic Purpura
Many medications can cause thrombocytopenic purpura, including some hypolipidemic agents. This is the fi rst case report of thrombocytopenic purpura due to the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, rosuvastatin. A 57-year-old Asian man developed multiple petechiae and purpura one month after receiving rosuvastatin in a dosage of 20 mg/day. When the drug was stopped and the ...
متن کاملDrug-Induced Immunologic Thrombocytopenic Purpura
The mechanism of drug-dependent immunologic thrombocytopenic purpura (DITP) was investigated by studying the sera of four patients with classic DITP (two with quinidine-, one with acetaminophen-. and one with phenazopyridinedependent antiplatelet antibody) using a solid-phase radioimmunoassay with 125l-staphylococcal protein A. Two forms of antiplatelet antibody could be demonstrated: one that ...
متن کاملAcute pancreatitis induced thrombotic thrombocytopenic purpura
CONTEXT Acute pancreatitis due to thrombotic thrombocytopenic purpura is a well recognized condition. Here, we are reporting a rare converse phenomenon, in which thrombocytopenic purpura occurred secondary to acute pancreatitis. CASE REPORT A 19-year-old male referred to our intensive care unit with diagnosis of acute pancreatitis with multi-organ dysfunction. He had history of severe abdomin...
متن کاملOpana® ER induced thrombotic thrombocytopenic purpura
We present the case of a patient who developed thrombotic thrombocytopenic purpura (TTP) following intravenous injection of Opana(®) ER. TTP reemerged after three months of abstinence with Opana misuse. This case report brings awareness to the possibility of developing TTP in those who misuse Opana, which is a growing concern.
متن کاملIpilimumab-induced thrombotic thrombocytopenic purpura (TTP)
BACKGROUND CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is to regulate the amplitude of the early stages of T-cell activation.1 Ipilimumab, a CTLA-4 blocking antibody, has been widely used for the treatment of patients with high risk and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 1993
ISSN: 0361-8609,1096-8652
DOI: 10.1002/ajh.2830430434